comms@paragonbiosci.com

57 items

May 25, 2022

Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital [...]
April 5, 2022

Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and [...]
March 1, 2022

Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
License agreement secures potential research of ecopipam [...]
December 16, 2021

Outstanding 2021 for Paragon Biosciences and Our Portfolio Companies
Chicago, Dec. 16, 2021 – Paragon Biosciences has [...]
December 7, 2021

PARAGON BIOSCIENCES EARNS 2021 GREAT PLACE TO WORK™ CERTIFICATION
Chicago, Dec. 7, 2021 – Paragon Biosciences [...]
November 10, 2021

Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Statistically significant, clinically meaningful results obtained on [...]
September 14, 2021

Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
Current enrollment for stuttering study is at [...]
June 22, 2021

Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
Paragon Biosciences’ Portfolio Company Focuses on Areas [...]

Previous 234 Next